What is the Purpose of this Study?
The purpose of this study is to compare the effects of an experimental drug called prasinezumab in patients with early Parkinson's disease who are taking standard medication (either rasagiline, selegiline, or levodopa) to manage their disease symptoms. Participants will be randomly assigned to receive either prasinezumab or placebo (inactive substance). Prasinezumab is a type of medication called a monoclonal antibody. Prasinezumab may clear away harmful forms of a specific protein to prevent damage to brain cells, potentially slowing the course of Parkinson's disease.
Eligibility
- Diagnosis of idiopathic PD based on MDS criteria with bradykinesia plus one of the other cardinal signs of PD (resting tremor, rigidity), without any other known or suspected cause of parkinsonism
- On symptomatic PD medication, with stable doses for at least 3 months prior to baseline
- A diagnosis of PD for at least 3 months to maximum 3 years at screening
- MDS-UPDRS Part IV score of 0 at screening and prior to randomization
Where can I participate?
Beverly
More about this Clinical Trial
What is the full name of this clinical trial?
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy And Safety Of Intravenous Prasinezumab In Participants With Early Parkinson's Disease